Only for enjoyable, what single inventory do you suppose will see large development - Web page 4

anthonypals wrote: ↑Sat Aug 26, 2023 5:09 pm
.. should you needed to guess your cash on one inventory to have large returns over the subsequent 5+ years what would it not be and why? ..

It would not be a giant guess, however Depth Therapeutics [INTS] is a biotech whose lead product is INT230-6, which is in human medical research for the remedy of refractory stable tumors, corresponding to smooth tissue sarcoma which is in section 3 trials; and neoadjuvant and metastatic triple unfavorable breast most cancers which is in Section 2 medical trials.

This text by E. Roudasev on SeekingAlpha is an effective abstract.
https://seekingalpha.com/article/469303 … emailshare

From the article:
“INT230-6 has a novel mechanism of motion, because it allows intratumoral supply of two well-known anti-cancer brokers utilizing a novel supply molecule.

INT230-6 induces substantial necrosis and creates a major immune response in numerous stable tumors, thereby making a ‘vaccine impact’. Drug dosing might be excessive as a result of little or no dispersion into the bloodstream is seen, and the security profile is kind of favorable. Earlier trials in people have seen tumor stabilization and shrinkage, lengthy intervals with out the formation of recent tumors, and a discount in illness signs.

Cisplastin, Vinblastine with SHAO: soluble in fats and water.

Contained in the tumor cells, the molecule disperses and the payloads exert their operate. Cisplatin binds the DNA and causes cell loss of life, and vinblastine shuts down replication. INT230-6 is ready to stay current within the tumor micro-environment, which is troublesome given the extremely dense and fatty nature of tumors.

INT230-6 doesn’t enter wholesome cells however solely most cancers cells. The drug doesn’t leak into and injury wholesome tissue. Because of this, INT230-6’s security profile seems to be slightly benign for a remedy, the essence of which it’s to kill most cancers cells within the physique.

Depth had introduced an abscopal impact, specifically measurement reductions of uninjected tumors (see additionally figures 7 and eight of the annual report), which might point out a persistent impact of the drug past the place of injection, and which I assume is linked to systemic immune activation. Systemic immune activation had already been established in preclinical work by the activation of T-cell reminiscence. “

And here’s a 2019 Forbes article on Lewis Bender, the founder and CEO of Depth Therapeutics.
https://www.forbes.com/sites/danieldamb … 4eec5f45e7